autoimmune encephalitis
Conditions
Interventions
Case series:None
Sponsors
Shenzhen People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical manifestations: acute or subacute onset; 2. Auxiliary examination: with one or more of the following auxiliary examination findings, or combined with related tumors. (1) Abnormal cerebrospinal fluid: leukocytosis of cerebrospinal fluid (>5x10^6/L); or cytology of cerebrospinal fluid shows lymphocytic inflammation; or oligoclonal zone of cerebrospinal fluid is positive; (2) Neuroimaging or electrophysiological abnormalities: abnormal T2 or FLAIR signal in MRI limbic system, unilateral or bilateral, or abnormal T2 or FLAIR signal in other regions (excluding non-specific white matter changes and stroke); or high limbic system on PET Metabolic alterations, or multiple cortical and/or basal ganglia hypermetabolism; or EEG abnormalities: focal epilepsy or epileptiform discharges (in or outside the temporal lobe), or diffuse or multifocal slow waves rhythm; (3) Specific types of tumors associated with AEs, such as limbic encephalitis with small cell lung cancer, anti-NMDAR encephalitis with teratoma. 3. Confirmatory test: positive for autoantibodies against neuronal surface antigens. Antibody detection mainly adopts indirect immunofluorescence assay (IIF). According to the antigen substrate, it is divided into two types: cell based assay (CBA) and tissue based assay (TBA). CBA uses transfected cells expressing neuronal cell surface antigens, and TBA uses animal brain tissue sections as antigen substrates. CBA has high specificity and sensitivity. The patient's paired cerebrospinal fluid and serum samples should be tested as much as possible, and the initial dilution titers of cerebrospinal fluid and serum are 1:1 and 1:10, respectively. 3. Exclude other possible causes; 4. Reasonably exclude other etiologies (refer to the differential diagnosis section of this consensus).
Exclusion criteria
Exclusion criteria: Undiagnosed, suspected autoimmune encephalitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cerebrospinal fluid;Mental symptoms; | — |
Countries
China
Contacts
Public ContactXu Qianhui
Department of Neurogy Shenzhen People's Hospital
Outcome results
None listed